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Immunitya b s t r a c t
Interplay between the gut microbiota and the immune system during HIV infection is currently a subject
of intense research. Several remarkable works were recently published and clearly associated structural
changes in its composition with disease progression markers. As well, specific commensal species were
reported to contribute to immune activation during the infection. However, the use of extremely varied
material and methods has led to inconsistent findings, sometimes discrepant. Herein, we propose to
review the main studies dedicated to the impact of HIV on the gut microbiota composition such as those
deciphering interplay between gut bacterial species and the immune system during the infection. We
finally provide exciting perspectives in modulating the HIV gut microbiome to lessen disease progression
as a novel adjuvant treatment.
 2016 Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
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Interplay between the gut microbiota and immune homeostasis
is a subject of current great interest, and induces intense research
in the field of infectious diseases. Thus, its role had been well
established in pathogenesis of diarrhea agents such as Clostridium
difficile [1] or Campylobacter [2]. Besides, potential protection
granted by the gut microbiota against pneumonia involving Kleb-
siella pneumoniae [3] or Staphylococcus aureus [4] was reported,
as gut flora promotes influenza vaccination [5]. Microbial translo-
cation and its association with immune activation and chronic
inflammation during HIV disease progression was a pioneering dis-
covery which highlights the role of microbiota in HIV pathogenesis
[6] (Fig. 1). It is also known that it drives immune homeostasis par-
ticularly in mucosal tissue and in return resident microbial com-
munities are partially controlled by the immune system [7,8].
Immune gut homeostasis is mainly based on the balance between
pro-inflammatory Th17 cells and inflammatory Foxp3+ regulatory
T cells, for which differentiation and maturation is influenced by
commensal microbes [9,10]. Thus, research dedicated to the evalu-
ation of the role of the gut microbiota during HIV infection is cur-
rently growing since the pioneering studies. If the literature clearly
suggests abrupt structural changes in the gut microbiota composi-
tion of HIV-infected individuals,-some of which were associated
with disease progression markers-, several discrepant results due
to heterogeneity in the methodology were reported (Table 1).
In addition, recent works highlighted that sexual practices are a
significant confounding factor in the analysis of HIV gut microbiotaFig. 1. Interactions between HIV, gut micr[11]. There is nevertheless a need to decipher its role in disease
progression, in an era when virological suppression is not sufficient
to control HIV-related mortality and morbidity [12–15]. Herein, we
review what is currently known about structural disruptions
reported in observational studies, potential pathobionts involved
in disease progression, and try to provide perspectives. Indeed,
the modulation of the gut microbiota during HIV infection would
probably be an important therapeutic adjuvant of the disease.Bibliographical methods
The literature review was conducted using the PubMed and
Google Scholar databases. Searched terms included keywords:
‘‘gut”, ‘‘intestinal”, ‘‘microbiota”, ‘‘microbiome”, ‘‘flora”, ‘‘HIV”. Only
human observational studies were selected according to the fol-
lowing criteria: i) high-throughput sequencing techniques, ii) tar-
geting 16S rDNA, iii) lower digestive tract. iv) inclusion of
controls (Table 1).Gut microbiota during HIV-infection
Diversity, the end of the debate?
Since the first published metagenomic approaches to decipher
the gut microbiota associated with HIV infection, numerous dis-
crepancies have emerged. Among them, diversity remains one of
the most controversial parameter, probably due to the complexityobiota and immune adaptative sytem.
Table 1
Observational studies dedicated to the assessment of gut microbiota associated with HIV infection. Red, increased; Green, decreased, grey, not different or not available.
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sometimes used in confusing way, and potentially explain this lack
of uniformity [16]. Richness only assesses the total number of spe-
cies in an area, or within a community and is widely measured by
the Chao1 index [17]. In another hand, a-diversity, which takes
also into account species distribution and relative abundance,
can be assessed by several metrics. The most commonly used are
the Shannon (or Shannon-Wiener) and the Simpson index, this lat-
ter being more specialized in dominant species [17]. Finally, phylo-
genetic diversity (PD) is a measure of biodiversity which
incorporates phylogenetic differences between species [18]. In
any event, the increase in publications dedicated to the topic pro-
vides more certainties. Indeed, one of the pioneering HIV observa-
tional studies conducted by Lozupone et al. using 454
pyrosequencing revealed a higher diversity in fecal microbiota
among HIV-infected patients which was assessed by both Shannon
index and PD [19]. Concomitantly, a study including multiple spec-
imen sampling yielded a lower diversity within subjects using PD
and richness [20]. If several works did not observe any differences
[21–24], the majority of the works published since then identified
a reduction of a-diversity or richness [20,25–27]
The impact of diversity changes during HIV infection has been
significantly brought to light in the recently published manuscript
by Nowak et al. In a cohort including 31 HIV-1 infected individuals
among whom 28 were viremic and 19 were receiving ART, Shan-
non and mutual Simpson diversity indices were significantly lower
in infected patients compared to controls [27]. In a stunning way,
Shannon index was a predictor of CD4 + T-cells count as its lowest
values concerned patients with the lowest CD4 + T-cells. Diversity
metrics were also correlated with several disease progression
markers (i.e., CD4/CD8 ratio or sCD14). Finally, introduction of
ART negatively impacted gut microbiota diversity; as such indices
were surprisingly lower after the introduction of antiviral therapy.
These findings were not invalidated by the work conducted by
Noguera-Julian. Indeed, if gut microbiota was found significantly
more rich and diverse in men who have sex with men (MSM) thanin non-MSM individuals, stratification for the HIV transmission
group confirmed a decreased bacterial richness in infected subjects
with a magnitude of 15–30%. This phenomenon seems especially
pronounced in subjects with an immune-virological discordant
phenotype, which partially confirms the link between diversity
and the CD4 T-cells count previously found [11]. Among other
studies, the stomach fluid flora was found less diverse among
HIV-infected subjects in a work recruiting few participants [28],
as it was the case for anal microbiota from 25 HIV-positive men
compared with 51 negative subjects [29]. Even when patients
received trimethoprim-sulfamethoxazole, association with gastric
fluid or anal microbiota persisted when the administration of
antibiotic was taking into consideration.
Taxonomic modifications associated with HIV-1 infection
The shift between Prevotella, -found increased in HIV
microbiota-, and Bacteroides, -found depleted-, belongs to the most
consistent changes reported at the genus level in HIV-infected
individuals [18–21,23] (Table 1). However, Nowak et al. observed
the opposite, and reduction of Prevotella became significant in
patients who underwent antiretroviral therapy when compared
to untreated subjects [27]. Only, Noguera et al. had shown that
fecal microbiota of MSM is consistently enriched in Prevotella,
whereas that of non-MSM is enriched in Bacteroides [11]. Accord-
ing to the descriptions of enterotypes [11,30], strong correlations
were found between Prevotella and other genera. Among them,
several were reported to be enriched during HIV infection, such
as Catenibacterium [19,20,23] or Odoribacter [19]. As well, genera
associated with Bacteroides enterotype were previously found
decreased by several investigators such as Parabacteroides [19],
Barnesiella [21–23,25] or Alistipes [21,24,26]. These data should
be carefully interpretated since the discovery of specific MSM
microbiota, and since most of the studies did not control sexual
behavior, to the best of our knowledge. One of the most constant
increase in relative abundance reported is that of Proteobacteria
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known to be involved in microbial translocation [21,22,24–27].
Yang et al. for their part found that Burkholderia and Bradyrhizo-
bium were the main Proteobacteria members to be enriched, and
concluded to a decrease of colonization resistance by environmen-
tal species [31].
The community belonging to the Clostridia class seems particu-
larly impacted by HIV infections, as depletion of Ruminococcaceae
and Lachnospiraceae families are frequently reported. This includes
species such as Ruminococcus bromii [24] or Faecalibacterium spp.
[20,23,25] for which depletion is strongly associated with inflam-
matory bowel disease (IBD) or Crohn’s disease [32,33]. Indeed,
depletion of the Lachnospiraceae family was reported during HIV
infection in three studies. Nowak et al. showed similar findings
but without statistical significance [27].
Also, Coprococcus sp. for which a role in inflammatory diseases
was hypothesized, had been frequently found decreased among
HIV-infected subjects [20,21,23,26].
Finally, it had been recently suggested that bacteria enriched in
HIV gut microbiota were tolerant to oxygen whereas those
depleted were strictly anaerobic [25]. Indeed, an increase in mem-
bers of Enterobacteriaceae and Enterococcaceae was found, with
several species for which correlations to immune activation or
translocation markers were positive. On the other hand, decreased
species belong to Ruminococcaceae, -including F. prausnitzii-,
Clostridiaceae and Lachnospiraceae and were negatively correlated
with these markers.
Good bugs, bad bugs
Even if changes in relative abundance of Prevotella and Bac-
teroides should be carefully interpreted since the publication of
Noguera-Julian, several interactions of these microorganisms with
immunity were reported as potentially relevant during HIV infec-
tions. Indeed, abundance of Prevotella spp. has been positively
linked to activated myeloid DCs and colonic T cells [21]. Later,
the same investigators had shown that high prevalence of Prevo-
tella copri/Prevotella stercorea is positively associated with CD40
expression on CD1c + mDCs [34]. We also note that the expression
of CD40 is correlated with mucosal HIV-1 viral load, cytokine pro-
duction, and a number of activated T cells.
In the same way, the depletion of Bacteroides spp. could have
immunological consequences. As an example, Bacteroides fragilis
expresses polysaccharide-A (PSA). The latter reduces the expansion
of Th17 cells through IL-10 induction, and thus prevents mucosal
barrier impairment [35]. A study screened for PSA-like elements
within prokaryotes genomes, and found that among species con-
taining information to encode for PSA, several of them were signif-
icantly decreased during HIV infection [36]. Besides, many
members of the gut microbiota intestinal drive T regulatory cells
(Treg) accumulation including Bacteroides massiliensis, Bacteroides
thetaiotaomicron, Bacteroides uniformis, or Parabacteroides distasonis
[37–39], Their depletion reported in HIV-infected individuals prob-
ably contributes to maintain a chronic inflammatory state. Finally,
the abundance of Bacteroides species were shown to be positively
associated with the presence in the GALT of Invariant natural Killer
T (iNKT), which are immunoregulatory cells, and their cytokine
production [40].
One of the most robust findings reported within studies dedi-
cated to the gut microbial shifts occurring during HIV infection is
the increase of Proteobacteria, in particular Enterobacteriaceae
(Table 1). This does not appear surprising since circulating
lipopolysaccharide (LPS), which is an essential component of the
outer membrane of Gram-negative bacteria, has been used as an
indicator of microbial translocation [6]. It has also been shown that
among immunologic HIV non-responders, circulating LPS andEnterobacteriaceae DNA were correlated with T-cell hyperactiva-
tion [41]. Among studies dedicated to the gut microbiota of HIV-
infected individuals, several associated disease progression mark-
ers with elevation of Proteobacteria abundance. Thus, an increase
in Enterobacteriaceae was associated with interferon levels, IL-1b
and sCD14 in a study enrolling subjects who underwent ART
[22], as an increase in Proteobacteria was linked with markers of
T cell activation, mucosal immune disruption, and chronic inflam-
mation in ART naïve patients [24]. Finally, elevation of Enterobacter
aerogenes in HIV-infected individuals was correlated with translo-
cation markers and chemokines [25]. If these mechanisms are not
completely elucidated, several in vitro studies yielded significant
interactions of Enterobacteriaceae members with gut immune
response. Exposure of Escherichia coli on human intestinal Lamina
Propria CD4 + T cells induced an increase in HIV-1 replication
when compared to exposure to the virus alone, alongside with
higher frequency of T-cell activation and increase of cytokines such
as IL-17 and IFN-c [42]. This finding is independent of LPS and
involved antigens which remain to be determined. Circulating
LPS is nevertheless a key of the disease progression, as it influences
mortality in HIV patients [43]. High levels are associated with
hypertension in HIV-infected subjects, independently of the T
CD4 cell count [44]. Interestingly, high abundance of Lactobacil-
lales was previously associated with less bacterial translocation
[45]. In response to LPS, the indoleamine 2,3-dioxygenase 1
(IDO1) pathway is activated [46]. This human enzyme induces
oxidative catabolism of tryptophan to kynurenine. If macrophages
and dendritic cells are usual IDO1 producers, it is also the case of
many gut microbiota members which were previously found
increased in the microbiota of HIV-infected patients [24]. This find-
ing is of interest, as tryptophan catabolites reduce the differentia-
tion of IL-17 secreting CD4 + T cells [47,48] and quinolinic acid
being involved in AIDS dementia [49,50]. Also, choline metabolites
(e.g. TMA, TMAO) are involved for their part in the cardiovascular
diseases process [51,52]
Finally, we reported that the decrease of Ruminococcus bromii in
HIV-infected patients was one the most significant taxonomic
modification of our study [25]. Interestingly, Dillon et al. have
shown that mDC activation and maturation status were negatively
correlated to low prevalence of several species including R. bromii
[34].Other microbiomes
Primarily focused on the gut microbiota, research dedicated to
the relationships between the human microbiome and HIV infec-
tion begins to expand to other human sites. Oral microbiota of
HIV-infected individuals slightly differs from that of uninfected
subjects, for which richness was described to be lower in a work
performing pyrosequencing applied on 37 samples from HIV-
infected subjects [53]. As well, commensal Streptococcus mitis
was found decreased whereas the proportion of Haemophilus para-
haemolyticus was increased. However, Moyes et al. found a greater
bacterial diversity within specimens from ART naïve HIV-infected
individuals, with an increase of Streptococcus mutans and Lacto-
bacillus using 16S rDNA fingerprinting profiling, whereas high
level of Candida species were yielded using real-time PCR [54].
Potentially pathogenic Veillonella, Prevotella, Megasphaera, and
Campylobacter were found enriched in the HIV lingual microbiome
[55]. Composition of the lung microbiome seems driven by the
antiretroviral therapy. Thus, the bacterial diversity was not differ-
ent in a study enrolling mainly patients who underwent ART [56],
whereas alpha diversity was decreased among untreated
HIV-infected patients [57]. The latter also differed from ART or
uninfected subjects with an increase in Veillonella, Rothia, and
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inflammation [58]. Finally, the abundance of Tropheryma whipplei,
the causative agent of Whipple’s disease, was found significantly
higher in HIV-infected subjects. This phenomenon is significantly
reduced in patients who underwent ART [59].
Concerning the relationship between the vaginal microbiota
and HIV infection, most of the studies were focused on HIV trans-
mission since a meta-analysis showed that bacterial vaginosis
increases the risk of HIV acquisition [60]. Indeed, the loss of Lacto-
bacillus species in favour of anaerobic bacteria including Gard-
nerella, Atopobium and Prevotella increases the risk of HIV
acquisition but also HIV transmission from HIV positive women
[61]. Recently, it had been also shown that a Lactobacillus crispa-
tus-dominant cervicovaginal mucus microbiota was associated
with a lower risk of HIV transmission than a Lactobacillus iners-
dominant microbiota [62]. If few data are available concerning
the evolution of the vaginal microbiome during HIV infection, the
analysis of cervicovaginal lavage samples yielded fluctuations of
relative abundance of various Lactobacillus species within the
vaginal microbiota depending on the disease’s progression [63].Perspectives
This review highlights the difficulty to provide clear conclusions
about the impact of HIV infection on the human gut microbiota.
Indeed, the heterogeneity of patients included (untreated or trea-
ted), sampling methods (mucosal or stool samples), extraction pro-
tocols, sequencing platforms, or taxonomic assignments induced a
variety of results, sometimes contradictory (Table 1). But defi-
nitely, the remarkable work conducted by Noguera-Julian put a
cat among the pigeons as most of the studies did not control, to
the best of our knowledge, sexual behavior of the controls
included. Besides, even if the information has reached investiga-
tors, such a methodology can be difficult to implement in future
research. However, it seems to be an inescapable step to decipher
microbiome alterations in HIV infections. Giving available data, the
enrichment of Proteobacteria and the loss of bacterial diversity
seem to be the more robust statements to date.
ART does not consistently restore microbial communities at
baseline. Intermediate levels of enrichment or depletion of several
bacterial groups in patients who underwent ART were however
reported, as restoration of a-diversity in some cases. Modulation
of the gut microbiota appears as an exciting perspective to reduce
chronic inflammation and immune activation in infected patients.
Several attempts, mostly probiotics, have been tried since
increased abundance of Lactobacillales of recently HIV-infected
subjects was associated with lower microbial translocation and
viral load, and higher CD4% (45). Administration of Lactobacilli
and Bifidobacteria were reported to decrease systemic immune
activation markers [64] or markers of inflammation in ART-
treated subjects [65]. Increase of T-lymphocytes had been also
yielded after supplementation with Lactobacilli. Besides, adminis-
tration of Saccharomyces boulardii decreased inflammation param-
eters and microbial translocation in patients virologically
suppressed [66]. Finally, a systematic review dedicated to the eval-
uation of daily probiotic use revealed that 7 out of 13 included
studies reported improvement of CD4 T cell count [67].
Besides, anti-oxidant supplementation could also be used as
adjuvant therapeutics even if there is no proof of concept. Recent
findings highlight an overgrowth of bacteria tolerant to oxygen
whilst strict anaerobes decrease in HIV-infected individuals [25].
In vitro works had also shown that ascorbic acid along with N-
acetylcysteine reduces early apoptosis of CD4 + T-cell induced by
LPS as selenium increases glutathione peroxidase activity in
latently infected T-cells, which become protected from hydrogenperoxide cytotoxic effect [68]. Human studies are also concerned,
as vitamin supplementation including vitamin A in early stage of
the disease lessens HIV progression and delays the introduction
of ART. HIV-infected individuals were shown to have low plasma
ascorbate levels [69] and introduction of vitamin E and C supple-
mentation resulted in a trend towards a reduction in viral load,
even if not significant [70]. Finally, a recent clinical trial highlights
that Omega 3 Fatty Acids Supplementation failed to reduce oxida-
tive stress in HIV-infected patients who underwent ART [71].
Finally it was recently shown that the metabolic alterations
observed in the HIV microbiota were clearly distinct from that
induced by systematic lupus erythematosus or C. difficile associ-
ated diarrhea [72], strengthening opportunities of adjuvant
treatments.Conclusions
If it is difficult for now to provide a clear picture of the impact of
HIV on the gut microbiota, though investigators had contributed to
fill knowledge gaps about its important role in the pathogenicity of
HIV disease. Further studies with stringent recruitments are
needed to evaluate the real influence of the virus on bacterial com-
munities rather than that of confounding factors. However, the lit-
erature currently offers several exciting perspectives, and the
modulation of the microbiome will probably be a significant part
of HIV therapeutics in the future.Conflicts of interest
None to declare.
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